AIDS Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
Research from H. Bussmann and colleagues provide new insights into HIV/AIDS
June 15th, 2009
"Numerous national antiretroviral (ARV) treatment initiatives offering protease inhibitor-sparing combination antiretroviral therapy (cART) have recently commenced in southern Africa, the first of which began in Botswana in January 2002. Evaluation of the efficacy and tolerability of various protease inhibitor-sparing cART regimens requires intensive study in the region, as does investigation of the development of drug resistance and the optimal means of sustaining adherence," investigators in the United States report. "The ''Tshepo'' Study is the first large-scale, randomized, clinical trial that addresses these important issues among HIV-1 subtype C-infected ARV...
Source: AIDS Weekly (2009-06-15)
|
